Nrf2在乳腺癌发生发展及产生耐药作用中的研究进展  

Advances in the Role of Nrf2 in the Development of Breast Cancer and the Development of Drug Resistance

作　　者：祖丽皮耶·买合木提 李鸿涛[1] 

机构地区：[1]新疆医科大学附属肿瘤医院乳腺甲状腺外科,新疆 乌鲁木齐

出　　处：《临床医学进展》2023年第10期16361-16367,共7页Advances in Clinical Medicine

摘　　要：乳腺癌是女性最常见的恶性肿瘤,化疗是乳腺癌治疗的重要手段之一,但其对治疗产生的耐药性给临床治疗带来了巨大的挑战。相关学者研究发现乳腺癌的发生和发展与体内异常的Nrf2及其相关信号通路的激活有关。本文将概述Nrf2及Nrf2/Keap1/ARE信号通路异常激活与乳腺癌发生发展、化疗耐药以及不良预后相关的研究进展。Breast cancer is the most common malignant tumor in women, and chemotherapy is one of the im-portant means of breast cancer treatment, but its resistance to treatment has brought great chal-lenges to clinical treatment. Related scholars have found that the occurrence and development of breast cancer are related to the activation of abnormal Nrf2 and its related signaling pathway in the body. In this article, we will summarize the research progress of Nrf2 and the abnormal activation of Nrf2/Keap1/ARE signaling pathway in relation to the development of breast cancer, chemotherapy resistance and poor prognosis.

关 键 词：NRF2 信号通路 乳腺癌 耐药 

分 类 号：R73[医药卫生—肿瘤]